SCHEMBL4067150

SCHEMBL4067150

COc1ccc(-c2cc3ncnc(N(CC4=COCO4)Cc4ccccc4)c3s2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.45
NPC1 O15118 3/20 0.45
KMT2A Q03164 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
MAP3K8 P41279 2/20 0.44
STK17B O94768 1/20 0.40
HSD17B2 P37059 1/20 0.39
EGFR P00533 3/20 0.39
CSF1R P07333 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PDPK1 O15530 1/20 0.38
ALDH1A1 P00352 1/20 0.38
HPGD P15428 1/20 0.38
NOS1 P29475 1/20 0.36
IKBKB O14920 1/20 0.35
MAPT P10636 1/20 0.35
PLCG2 P16885 1/20 0.35
KIT P10721 2/20 0.35
PAX8 Q06710 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3930210 0.93 HSD17B2 (0.41) RAB9ANPC1KMT2ATDP1MAP3K8
SCHEMBL4069660 0.91 IKBKB (0.41) RAB9ANPC1MAP3K8STK17BEGFR
SCHEMBL4066630 0.90 MAP3K8 (0.41) MAP3K8STK17BEGFRIKBKBKIT
SCHEMBL4066698 0.90 MAP3K8 (0.45) RAB9ANPC1KMT2ATDP1MAP3K8
SCHEMBL3936370 0.89 EGFR (0.37) RAB9ANPC1KMT2ATDP1MAP3K8
SCHEMBL3938279 0.89 FLT1 (0.46) KMT2ATDP1MAP3K8STK17BEGFR
SCHEMBL4064216 0.89 STK17B (0.41) RAB9ANPC1KMT2ATDP1MAP3K8
SCHEMBL4068418 0.89 KIT (0.43) RAB9ANPC1MAP3K8STK17BEGFR
SCHEMBL3928357 0.88 EGFR (0.44) RAB9ANPC1KMT2ATDP1MAP3K8
SCHEMBL4071472 0.88 IKBKB (0.35) MAP3K8STK17BEGFRIKBKBKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US claimed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP claimed
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR BAYER SHERING PHARMA AG (DE) 2009-02-12 US disclosed
EP-2014663-A1 Thieno-pyrimidyl amines as modulators of EP2 receptors Bayer Schering Pharma AG (DE) 2009-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042878-A1 THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR PTGER2, PTGER1, PTGDR2 RAB9A 3562/4885NPC1 3333/4885KMT2A 2055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.